NASDAQ:RCKT

Rocket Pharmaceuticals - RCKT Stock Forecast, Price & News

$16.29

-0.46 (-2.75%)

(As of 03/30/2023 12:00 AM ET)

Add

Compare

Today's Range: $16.11
▼
$17.11
50-Day Range: $15.79
▼
$22.60
52-Week Range: $7.57
▼
$23.48

Volume: 900,520 shs
Average Volume: 860,804 shs
Market Capitalization: $1.29 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $52.58

Institutional Ownership

Rocket Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 222.8% Upside
$52.58 Price Target
Short Interest: Bearish
11.25% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: 0.16
Based on 12 Articles This Week
Insider Trading: Selling Shares
$300,214 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.31) to ($2.03) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

77th out of 1,009 stocks

Pharmaceutical Preparations Industry

24th out of 494 stocks

4.5

Analyst's Opinion

Consensus Rating
Rocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $52.58, Rocket Pharmaceuticals has a forecasted upside of 222.8% from its current price of $16.29.
Amount of Analyst Coverage
Rocket Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
11.25% of the outstanding shares of Rocket Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 9.5.
Change versus previous month
Short interest in Rocket Pharmaceuticals has recently increased by 7.46%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Rocket Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Rocket Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Rocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Rocket Pharmaceuticals is -0.81.

2.3

News and Social Media Coverage

News Sentiment
Rocket Pharmaceuticals has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Rocket Pharmaceuticals this week, compared to 6 articles on an average week.
Search Interest
Only 29 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.
MarketBeat Follows
17 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 89% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $300,214.00 in company stock.
Percentage Held by Insiders
33.67% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
93.23% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($3.31) to ($2.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rocket Pharmaceuticals is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rocket Pharmaceuticals is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rocket Pharmaceuticals has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Stock News Headlines

March 30, 2023 | cnbc.com

Rocket Mortgage launches a credit card to help you save for or pay off a home

March 28, 2023 | americanbankingnews.com

Q1 2023 Earnings Forecast for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Issued By William Blair

March 30, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!

March 27, 2023 | technews.tmcnet.com

Premier Valet Ski Storage Provider, Rocket Closet, Teams Up with Surefoot for Hassle-Free Travel

March 25, 2023 | msn.com

Rocket Lab reveals big supplier deal with mystery mega constellation customer

March 24, 2023 | msn.com

Rocket Lab lifts off with 2 satellites onboard after unexpected solar storm delays launch

March 23, 2023 | msn.com

Destiny 2: How to Grapple onto Your Rocket

March 23, 2023 | nytimes.com

Relativity Space Launches First 3-D Printed Rocket

March 30, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

March 23, 2023 | usnews.com

Relativity's Debut Rocket Launch Proves Durability, Fails in Space

March 23, 2023 | americanbankingnews.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $52.58 Average Target Price from Brokerages

March 22, 2023 | msn.com

Sir Elton John left stunned as he learns true inspiration behind Rocket Man

March 21, 2023 | msn.com

Watch Rocket Lab launch 2 satellites, recover booster early on March 22

March 21, 2023 | forbes.com

Rocket League’s Hottest Battlecar Is In The Item Shop For A Limited Time

March 20, 2023 | msn.com

With Team Rocket retired, are these the Pokémon anime’s new villains?

March 19, 2023 | nasdaq.com

Rocket Pharmaceuticals (RCKT) Shares Cross Below 200 DMA

March 19, 2023 | msn.com

Rocket League: 10 Best Toppers, Ranked

March 17, 2023 | msn.com

Rocket Lab launches two radar imaging satellites from Virgina's Eastern Shore

March 17, 2023 | bizjournals.com

Rocket Lab plans rescheduled Virginia launch for Thursday

March 16, 2023 | msn.com

Siddharth Roy Kapur, Nikkhil Advani Talk SonyLIV’s ‘Rocket Boys’ Season 2

March 14, 2023 | msn.com

Pokémon’s Team Rocket blasts off for what may be the final time

March 13, 2023 | forbes.com

Rocket Launch Visible To 100 Million Will Look Like A Speeding Star

March 1, 2023 | finance.yahoo.com

Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference

March 1, 2023 | markets.businessinsider.com

What 6 Analyst Ratings Have To Say About Rocket Pharmaceuticals

March 1, 2023 | finance.yahoo.com

What Makes Rocket Pharmaceuticals (RCKT) Shares Attractive?

February 27, 2023 | msn.com

Rocket Pharmaceuticals GAAP EPS of -$0.92 misses by $0.10

February 27, 2023 | finance.yahoo.com

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Company Calendar

Last Earnings: 2/27/2023
Today: 3/30/2023
Next Earnings (Estimated): 5/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RCKT
CUSIP: N/A
CIK: 1281895
Web: www.rocketpharma.com
Phone: (609) 659-8001
Fax: 646-224-9585
Employees: 151
Year Founded: 2018

Price Target and Rating

Average Stock Price Forecast: $52.58
High Stock Price Forecast: $75.00
Low Stock Price Forecast: $34.00
Forecasted Upside/Downside: +222.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-221,860,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -53.39%
Return on Assets: -47.69%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 9.29
Quick Ratio: 9.29

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.47 per share
Price / Book: 2.52

Miscellaneous

Outstanding Shares: 79,350,000
Free Float: 52,632,000
Market Cap: $1.29 billion
Optionable: Optionable
Beta: 1.23

Social Links

Key Executives

Gaurav D. Shah
Chief Executive Officer & Director

Kinnari Patel
President & Chief Operating Officer

John C. Militello
Treasurer, Chief Financial & Accounting Officer

Jonathan David Schwartz
Chief Medical Officer & SVP-Clinical Development

Mayo Pujols
Chief Technical Officer & Executive Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RCKT Stock - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings or view top-rated stocks.
What is Rocket Pharmaceuticals' stock price forecast for 2023?: 12 analysts have issued 12-month price targets for Rocket Pharmaceuticals' stock. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they expect the company's share price to reach $52.58 in the next twelve months. This suggests a possible upside of 222.8% from the stock's current price.
View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts.
How have RCKT shares performed in 2023?: Rocket Pharmaceuticals' stock was trading at $19.57 at the beginning of 2023. Since then, RCKT shares have decreased by 16.8% and is now trading at $16.29.
View the best growth stocks for 2023 here.
When is Rocket Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our RCKT earnings forecast.
How were Rocket Pharmaceuticals' earnings last quarter?: Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) posted its earnings results on Monday, February, 27th. The biotechnology company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.10. During the same period in the prior year, the business earned ($0.69) earnings per share.
What ETFs hold Rocket Pharmaceuticals' stock?: ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Global X Guru Index ETF (GURU), Harbor Health Care ETF (MEDI), ALPS Medical Breakthroughs ETF (SBIO), Harbor Disruptive Innovation ETF (INNO), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Rocket Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).
What is Rocket Pharmaceuticals' stock symbol?: Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."
Who are Rocket Pharmaceuticals' major shareholders?: Rocket Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Maverick Capital Ltd. (4.49%), RA Capital Management L.P. (3.18%), Price T Rowe Associates Inc. MD (2.49%), Avidity Partners Management LP (2.02%), Dimensional Fund Advisors LP (1.49%) and Geode Capital Management LLC (1.46%). Insiders that own company stock include Gaurav Shah, Gotham Makker, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends.
How do I buy shares of Rocket Pharmaceuticals?: Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Rocket Pharmaceuticals' stock price today?: One share of RCKT stock can currently be purchased for approximately $16.29.
How much money does Rocket Pharmaceuticals make?: Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.29 billion. The biotechnology company earns $-221,860,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis.
How many employees does Rocket Pharmaceuticals have?: The company employs 151 workers across the globe.
How can I contact Rocket Pharmaceuticals?: Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585.

This page (NASDAQ:RCKT) was last updated on 3/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Rocket Pharmaceuticals - RCKT Stock Forecast, Price & News

Rocket Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

RCKT Stock News Headlines

RCKT Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

RCKT Stock - Frequently Asked Questions

Overall MarketRank^™